Royal Bank Of Canada Has Lowered Expectations for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective decreased by analysts at Royal Bank Of Canada from $14.00 to $13.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price objective suggests a potential upside of 97.57% from the company’s current price.

BCRX has been the subject of several other reports. Needham & Company LLC dropped their target price on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, November 4th. TD Cowen began coverage on BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 target price on the stock. JMP Securities lifted their price target on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a report on Wednesday, October 15th. Citizens Jmp reduced their price objective on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a research note on Wednesday, November 5th. Finally, HC Wainwright upped their price target on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.50.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $6.58 on Friday. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.31. The business has a fifty day moving average price of $7.28 and a 200 day moving average price of $7.58. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -131.60, a PEG ratio of 0.36 and a beta of 0.80.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.01). The firm had revenue of $159.40 million for the quarter, compared to analysts’ expectations of $162.91 million. BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The business’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.07) EPS. On average, research analysts anticipate that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 21,773 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $7.65, for a total transaction of $166,563.45. Following the sale, the insider owned 398,751 shares in the company, valued at $3,050,445.15. This represents a 5.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 183,453 shares of company stock valued at $1,330,965 over the last three months. 5.10% of the stock is owned by insiders.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Universal Beteiligungs und Servicegesellschaft mbH raised its position in shares of BioCryst Pharmaceuticals by 7.7% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 1,288 shares during the period. Royal Bank of Canada increased its stake in BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 1,458 shares during the period. Captrust Financial Advisors increased its stake in shares of BioCryst Pharmaceuticals by 7.4% during the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock valued at $198,000 after acquiring an additional 1,527 shares during the period. Main Management ETF Advisors LLC increased its position in shares of BioCryst Pharmaceuticals by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 112,128 shares of the biotechnology company’s stock valued at $1,005,000 after purchasing an additional 1,824 shares during the period. Finally, Counterweight Ventures LLC grew its holdings in BioCryst Pharmaceuticals by 2.1% during the fourth quarter. Counterweight Ventures LLC now owns 95,384 shares of the biotechnology company’s stock worth $744,000 after acquiring an additional 2,000 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.